Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.
Jean‐Charles Soria(Inserm), Michael Millward(The University of Western Australia), Jennifer R. Brown(Dana-Farber Cancer Institute), Charlotte Lemech(Unknown), T.R. Jeffry Evans(Leiden University Medical Center), Rastislav Bahleda(Institut Gustave Roussy), Ruth Plummer(National Health Service), Malcolm Ranson(Cancer Research UK Manchester Institute), Gérard Zalcman(Université Claude Bernard Lyon 1), Jolly Mazumdar(Howard Hughes Medical Institute), Sarah P. Blagden(Churchill Hospital), Noelia Nebot(Research Triangle Park Foundation), D. Gibson, Antoine Hollebecque(Institut Gustave Roussy), Ronald A. Fleming(Research Triangle Park Foundation), Sharon C. Murray(BioCryst Pharmaceuticals (United States)), Hui Gan(Austin Hospital), Vijay Gopal Reddy Peddareddigari(GlaxoSmithKline (United States)), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute)
Cited by 14
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k